EBITDA

After a major business sale, Elutia is launching NXT-41x, an antibiotic biomatrix designed to combat the high rate of infection in breast reconstruction.

Rigetti Computing pushes back its Cepheus-1-108Q launch to Q1 2026, a move that rattled investors but underscores the quantum industry's tough race for fidelity.

With its first MASH drug a success, Madrigal aims to redefine treatment by combining it with a newly licensed Pfizer asset. Is this the future?

Koppers Holdings navigates a key leadership change as CFO Jimmi Sue Smith retires. Veteran Bradley Pearce takes the helm as interim financial chief.

The fintech platform grew twice as fast as the overall market in 2025, fueled by tech innovation and a surge in multi-protocol trading adoption.

Aesthetics firm Evolus reports its first profitable quarter and robust growth, banking on new products and international markets to defy industry slowdowns.

Lightspeed's new conversational AI acts as a business partner for retailers and restaurants, turning complex data into simple answers to boost performance.

With new trials in myositis and pediatrics, Cartesian Therapeutics pioneers an outpatient cell therapy, moving beyond cancer to treat chronic autoimmune diseases.

The Oncology Institute promotes new CIO and CPO, signaling a strategic push into AI-driven care and robust talent management to dominate the market.

KB Home launches its new Somerset community in Victorville, tapping into high demand with personalized, energy-efficient homes priced from the mid-$400,000s.

With the appointment of Dr. Stephen Eck, Flare Therapeutics signals a major push to advance its first-in-class cancer therapies targeting transcription factors.

With $82M in funding and novel gene insertion technology, Averna Therapeutics is poised to make waves at the pivotal J.P. Morgan Healthcare Conference.

With record revenue and a bold AI strategy, Opera heads to a key investor conference. Can its 'agentic' browsers redefine the web and win market share?

Facing complex 2025 tax changes? H&R Block is offering new DIY clients a free professional review, blending digital convenience with expert assurance.

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.

With a new board chair, regulatory backing, and an AI platform, GC Therapeutics is targeting MS and diabetes with next-generation cell therapies.

The biotech firm now expects Phase 2 results in Q3 2026, accelerating hope for new CNS treatments and signaling strong operational momentum to investors.

Indonesia Energy Corp. starts pre-drilling for two new wells in Sumatra, a key move in its growth strategy and a boost for national energy security.

Predis.ai's new AI promises to slash video ad costs and production time, empowering small businesses and challenging traditional marketing workflows.